Purple Biotech
PPBT

ADSs offered 3,055,000 ADSs representing 611,000,000 Ordinary Shares by the company

ADSs offered 472,668 ADSs representing 94,533,600 Ordinary Shares by the company

ADSs offered 2,430,000 ADSs,representing 24,300,000 Ordinary Shares by the company.

Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 38,888,892 of the Company’s ordinary shares represented by American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 19,444,446 ADSs, at a combined purchase price of $0.90 per ADS and associated warrant to purchase 0.5 of an ADS for aggregate gross proceeds of approximately $35.0 million. Each ADS represents one ordinary share, no par value, of Kitov. The warrants have an exercise price of $0.90 per ADS and are exercisable at any time upon issuance and expire five years from the date of issuance.

From January 1,2018 to January 7,2019 Issuance of ADSs Issuance of shares Share based payments Exercise of warrants Further to its Report on Form 6-K dated December 19, 2018, in which Kitov Pharma Ltd. (the “Company” or the “Registrant”) announced the results of its 2018 Annual General Meeting of Shareholders of the Company held on December 19, 2018, at which, amongst other matters on the agenda, the shareholders of the Company voted to approve a 1-for-20 reverse share split of the Company’s share capital, effective on the date to be announced by the Company, and to approve the applicable amendments to each of the Company’s Memorandum of Association and Amended and Restated Articles of Association to reflect such reverse split, as set forth under Proposal 8 in the Company’s Proxy Statement for the Annual Meeting that was attached as Exhibit 99.2 to a Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on November 9, 2018 (the “Proxy Statement”), the Company is announcing that the record date for determining which holders of the Registrant’s ordinary shares, and which holders of options to purchase the Registrant’s ordinary shares, will have their holdings adjusted as a result of the 1-for-20 reverse share split (as described in the Proxy Statement) will be the close of business on Friday January 4, 2019.

from January 1, 2018 to June 30, 2018 Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance cost Issuance of shares due to RSUs vesting Exercise of warrants Share issuance due to acquisition of Non-controlling interest Share-based payments

from December 31, 2014 to December 31, 2015 Issuance of ADSs and warrants, net of issuance costs Issuance of shares, net of issuance costs Share issuance deriving from a strategic cooperation agreement Share issuance due to meeting of milestone Exercise of warrants